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Background: In the phase III LUX-Head & Neck 1 (LHN1) trial, afatinib signiﬁcantly improved progression-free survival
(PFS) versus methotrexate in recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
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patients progressing on/after platinum-based therapy. This report evaluates afatinib efﬁcacy and safety in prespeciﬁed
subgroups of patients aged ≥65 and <65 years.
Patients and methods: Patients were randomized (2:1) to 40 mg/day oral afatinib or 40 mg/m2/week intravenous
methotrexate. PFS was the primary end point; overall survival (OS) was the key secondary end point. Other end points
included: objective response rate (ORR), patient-reported outcomes, tumor shrinkage, and safety. Disease control rate
(DCR) was also assessed.
Results: Of 483 randomized patients, 27% (83 afatinib; 45 methotrexate) were aged ≥65 years (older) and 73% (239
afatinib; 116 methotrexate) <65 years (younger) at study entry. Similar PFS beneﬁt with afatinib versus methotrexate was
observed in older {median 2.8 versus 2.3 months, hazard ratio (HR) = 0.68 [95% conﬁdence interval (CI) 0.45–1.03],
P = 0.061} and younger patients [2.6 versus 1.6 months, HR = 0.79 (0.62–1.01), P = 0.052]. In older and younger
patients, the median OS with afatinib versus methotrexate was 7.3 versus 6.4 months [HR = 0.84 (0.54–1.31)] and 6.7
versus 6.2 months [HR = 0.98 (0.76–1.28)]. ORRs with afatinib versus methotrexate were 10.8% versus 6.7% and 10.0%
versus 5.2%; DCRs were 53.0% versus 37.8% and 47.7% versus 38.8% in older and younger patients, respectively.
In both subgroups, the most frequent treatment-related adverse events were rash/acne (73%–77%) and diarrhea
(70%–80%) with afatinib, and stomatitis (43%) and fatigue (31%–34%) with methotrexate. Fewer treatment-related dis-
continuations were observed with afatinib (each subgroup 7% versus 16%). A trend toward improved time to deterioration
of global health status, pain, and swallowing with afatinib was observed in both subgroups.
Conclusions: Advancing age (≥65 years) did not adversely affect clinical outcomes or safety with afatinib versus
methotrexate in second-line R/M HNSCC patients.
Clinical trial registration: NCT01345682 (ClinicalTrials.gov).
Key words: afatinib, methotrexate, HNSCC, second-line, phase III, older
introduction
Head and neck squamous cell carcinoma (HNSCC), including
cancers of the lip, oral cavity, larynx, and pharynx, represents
the seventh most common malignancy worldwide, with
>650 000 cases diagnosed in 2012 [1]. Of these cases, 37% were
older patients (≥65 years), 15% aged ≥75 years. These statistics
are consistent with the EUROCARE-5 population-based study
(1999–2007), which also reported decreased survival for head
and neck cancer patients of advancing age at diagnosis (5-year
relative survival: 56%, 38%, and 34% in patients aged ≤44, 65–
74, and ≥75 years, respectively) [2]. There are no speciﬁc
therapy guidelines for older patients with HNSCC, and treat-
ment is often suboptimal due to poor functional status, high co-
morbidity burden and limited tolerability of standard therapies
[3, 4]. For recurrent and/or metastatic (R/M) HNSCC patients
progressing on/after ﬁrst-line platinum therapy, these age-asso-
ciated factors add to an already dismal prognosis and limited
treatment options. Second-line treatment for R/M HNSCC pri-
marily consists of single-agent or combination chemotherapy
(e.g. methotrexate, taxanes) [5, 6]. However, older patients often
do not receive these therapies due to the high risk of chemother-
apy-induced toxicities, which can lead to treatment intolerance
and poorer outcomes [3, 4].
Despite advancements in the development of targeted therap-
ies as similarly efﬁcacious and potentially less toxic options
compared with chemotherapy, only one targeted therapy, the
anti-epidermal growth factor receptor (EGFR) monoclonal anti-
body, cetuximab, is approved for second-line R/M HNSCC, and
only in the United States [7]. There are no published studies
evaluating cetuximab in older R/M HNSCC patients, although
subgroup analyses in a phase II study of cetuximab following
the failure of a platinum-based therapy reported similar efﬁcacy
outcomes in patients aged <65 or ≥65 years; safety was not
analyzed according to age [7]. In contrast, a phase III study of
cetuximab combined with platinum-based therapy for ﬁrst-line
R/M disease reported reduced clinical beneﬁt in subgroup ana-
lyses of patients aged ≥65 years [8]. In light of these limited
data, there remains signiﬁcant need to identify effective and
manageable treatments for older HNSCC patients.
Afatinib, an oral, irreversible ErbB family blocker, binds to
human EGFR 1, 2, and 4 and inhibits signaling from all ErbB
family members [9]. In the phase III LUX-Head & Neck 1
(LHN1) trial, afatinib signiﬁcantly improved progression-free
survival (PFS) and patient-reported outcomes versus methotrex-
ate in R/M HNSCC patients progressing on/after platinum-
based therapy [10]. Afatinib was associated with a predictable
and manageable adverse event (AE) proﬁle, with fewer treat-
ment-related dose reductions, discontinuations and fatal events
compared with methotrexate. This report evaluates the efﬁcacy
and safety of afatinib in prespeciﬁed age subgroups of ≥65 and
<65 years in LHN1.
materials andmethods
patients
Complete eligibility criteria were previously reported [10]. Eligible patients
were aged ≥18 years, had an Eastern Cooperative Oncology Group perform-
ance status (ECOG PS) of 0/1, and histologically or cytologically conﬁrmed
squamous cell carcinomas of the oral cavity, oropharynx, hypopharynx or
larynx, which had recurred or metastasized and were not amenable for
salvage surgery or radiotherapy. Patients had documented progression based
on investigator assessment [Response Evaluation Criteria in Solid Tumors
version 1.1 (RECIST v1.1)] following ≥2 cycles of cisplatin or carboplatin for
R/M disease; treatment with >1 systemic regimen in this setting was not
allowed. Prior EGFR-targeted antibody therapy, but not EGFR tyrosine
kinase inhibitors, was allowed.
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study design
In this global, phase III, open-label trial, patients were randomized (2:1)
to 40 mg/day oral afatinib or 40 mg/m2/week intravenous methotrexate,
stratiﬁed by ECOG PS (0/1) and prior EGFR-targeted antibody therapy for
R/M disease (yes/no). Details on dose modiﬁcations were reported [10].
Treatment continued until disease progression, unacceptable toxicity, or
withdrawal.
The primary end point was PFS (independent central review); overall sur-
vival (OS) was the key secondary end point. Other end points included ob-
jective response, tumor shrinkage, patient-reported outcomes of disease
symptoms and quality of life [QoL; European Organization for Research and
Treatment of Cancer (EORTC) quality-of-life questionnaire C30 and its
head and neck cancer-speciﬁc module], and safety; disease control was also
assessed.
The study protocol, designed in accordance with the Declaration of
Helsinki, the International Conference on Harmonization Guideline for
Good Clinical Practice, and applicable region-speciﬁc regulatory require-
ments, was approved by Independent Ethics Committees at each center. All
patients provided written informed consent.
assessments
Tumor response was assessed by investigators and independent central
review (RECIST v1.1) every 6 weeks for the ﬁrst 24 weeks, and every 8 weeks
thereafter [10]. Safety was monitored weekly, with incidence and intensity
of AEs graded according to the National Cancer Institute-Common
Terminology Criteria for Adverse Events (version 3.0).
statistical analysis
Complete details on statistical analyses were reported [10]. Efﬁcacy analyses
included all randomized patients (intent-to-treat population); safety analyses
included all treated patients (randomized patients receiving ≥1 dose of study
drug). PFS and OS were analyzed following a hierarchical testing procedure
consisting of a stratiﬁed log-rank test with strata used for randomization on
PFS followed by OS. The Kaplan–Meier method was used to estimate PFS
and OS, and hazard ratios (HRs) for afatinib versus methotrexate were
derived using a stratiﬁed Cox proportional hazards model. Predeﬁned age
subgroups included ≥65 and <65 years; a Cox proportional hazards model
was used to explore subgroup by treatment interaction. Statistical analyses
were performed with SAS (version 9.2).
results
patients
Of 483 randomized patients, 128 (27%) were aged ≥65 years
(afatinib, n = 83; methotrexate, n = 45), and 355 (73%) aged <65
years (afatinib, n = 239; methotrexate, n = 116) (supplementary
Figure S1, available at Annals of Oncology online), further
described as ‘older’ and ‘younger’, respectively. The median
(range) age was 71 (65–82) and 71 (65–88) years for patients
treated with afatinib and methotrexate in the older subgroup,
and 57 (32–64) and 55 (32–64) years in the younger subgroup.
Approximately 15% (n = 71) of patients were aged ≥70 years
(afatinib, n = 47; methotrexate, n = 24) and 7% (n = 32) aged
≥75 years (afatinib, n = 22; methotrexate, n = 10) due to small
patient numbers; no further analyses were conducted in these
exploratory age subgroups.
Baseline disease characteristics were generally well balanced
(Table 1). A larger proportion of older patients randomized
to methotrexate had an ECOG PS of 1 compared with the
afatinib arm, although patient numbers in this arm were small.
Compared with the younger subgroup, a larger proportion of
older patients had oral cavity primary tumor site, and fewer
received prior cisplatin for R/M disease. More patients in the
older subgroup received prior radiotherapy with curative intent
and fewer received chemoradiation. Slightly higher incidences of
diabetes and hypertension were noted in older patients (supple-
mentary Table S1, available at Annals of Oncology online).
There were no notable differences in baseline concomitant med-
ications (data on ﬁle).
treatment exposure
Median (range) treatment durations with afatinib and metho-
trexate were 84 (6–512) and 43 (1–337) days in older patients,
and 80 (2–546) and 43 (1–442) days in younger patients. The
majority of older (afatinib, 82%; methotrexate, 82%) and
younger (afatinib, 86%; methotrexate, 85%) patients received
≥80% of the assigned study medication. The majority of afati-
nib-treated patients received the drug in tablet form (older, 80%;
younger, 73%) compared with feeding tube administration
(older, 13%; younger, 22%) or oral dispersion (older, 7%;
younger, 5%).
efﬁcacy
Treatment effects on survival outcomes were similar between
subgroups. The median PFS with afatinib versus methotrexate
was 2.8 versus 2.3 months {HR = 0.68 [95% conﬁdence interval
(CI) 0.45–1.03], P = 0.061} in older patients and 2.6 versus 1.6
months [HR = 0.79 (0.62–1.01), P = 0.052] in younger patients
(Figure 1A). The median OS with afatinib and methotrexate was
7.3 versus 6.4 months [HR = 0.84 (0.54–1.31), P = 0.436] in
older patients and 6.7 versus 6.2 months [HR = 0.98 (0.76–
1.28), P = 0.910] in younger patients (Figure 1B).
Objective response rates (ORRs) with afatinib versus metho-
trexate were 10.8% versus 6.7% [odds ratio (OR) = 1.7 (95% CI
0.44–6.64)] in older patients, and 10.0% versus 5.2% [OR = 2.0
(0.81–5.15)] in younger patients. Disease control rates (DCRs)
with afatinib versus methotrexate were 53.0% versus 37.8%
[OR = 1.9 (0.89–3.90)] in older patients and 47.7% versus 38.8%
[OR = 1.4 (0.92–2.26)] in younger patients. A higher percentage
of patients in each subgroup experienced tumor shrinkage from
baseline with afatinib versus methotrexate, with no notable dif-
ferences between the subgroups (Figure 2).
Approximately 50% of patients in each subgroup received
subsequent anticancer therapy following discontinuation of
study treatment, with the majority (∼92% in each subgroup)
receiving subsequent chemotherapy as monotherapy or in
combination (supplementary Table S2, available at Annals of
Oncology online).
safety
The safety proﬁles of afatinib and methotrexate were similar in
older and younger patients (Table 2). Treatment-related AEs oc-
curred in ≥85% of patients across treatment groups in each age
subgroup, with grade 3/4 AEs in 32%–40% of patients (Table 2).
In each subgroup, the most frequent grade 3/4 treatment-related
AEs consisted of rash/acne, diarrhea, stomatitis, and fatigue
with afatinib, and stomatitis and hematologic AEs (e.g. anemia,
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Table 1. Patients’ demographic and baseline characteristics by age subgroup
Characteristic Patients aged ≥65 years Patients aged <65 years
Afatinib (N = 83) Methotrexate (N = 45) Afatinib (N = 239) Methotrexate (N = 116)
Gender, n (%)
Male 68 (82) 37 (82) 207 (87) 100 (86)
Female 15 (18) 8 (18) 32 (13) 16 (14)
Age (years)
Median (range) 71 (65–82) 71 (65–88) 57 (32–64) 55 (32–64)
Age category, n (%)
<75 years 61 (73) 35 (78) 239 (100) 116 (100)
≥75 years 22 (27) 10 (22) 0 (0) 0 (0)
ECOG PS, n (%)
0 23 (28) 7 (16) 66 (28) 35 (30)
1 60 (72) 38 (84) 173 (72) 81 (70)
Smoking habits, n (%)a
Median (range) pack years 50.0 (4.5–156.0) 43.0 (3.7–156.0) 40.0 (1.0–130.0) 36.0 (0.6–225.0)
<10 pack years 18 (22) 8 (18) 38 (16) 23 (20)
≥10 pack years 60 (72) 34 (76) 195 (82) 92 (79)
Unknown 5 (6) 3 (7) 6 (3) 1 (1)
Alcohol consumption, n (%)a
≤7 units/week 65 (78) 40 (89) 185 (77) 84 (72)
>7 units/week 15 (18) 5 (11) 43 (18) 28 (24)
Unknown 3 (4) 0 (0) 11 (5) 4 (3)
Weight loss in prior 3 months, n (%)a
None 59 (71) 27 (60) 161 (67) 80 (69)
≤5% 12 (14) 8 (18) 35 (15) 19 (16)
>5% and ≤10% 6 (7) 4 (9) 27 (11) 10 (9)
>10% 4 (5) 3 (7) 5 (2) 3 (3)
Unknown 2 (2) 3 (7) 11 (5) 4 (3)
Primary tumor site, n (%)a
Oral cavity 29 (35) 17 (38) 65 (27) 25 (22)
Oropharynx 26 (31) 10 (22) 73 (31) 44 (38)
Hypopharynx 12 (14) 9 (20) 51 (21) 21 (18)
Larynx 16 (19) 9 (20) 50 (21) 26 (22)
Median time since first diagnosis, years (range)a 2.3 (0.4–27.1) 1.7 (0.6–21.7) 1.9 (0.3–21.0) 2.4 (0.5–18.2)
<2, n (%) 37 (45) 24 (53) 126 (53) 47 (41)
≥2, n (%) 46 (55) 21 (47) 112 (47) 68 (59)
Unknown, n (%) 0 (0) 0 (0) 1 (<1) 1 (1)
Recurrence and metastases, n (%)a
Recurrent only 28 (34) 22 (49) 78 (33) 39 (34)
Metastatic only 10 (12) 8 (18) 36 (15) 10 (9)
Both 43 (52) 15 (33) 121 (51) 62 (53)
Unknown 2 (2) 0 (0) 4 (2) 5 (4)
p16 status,b n (%)a
Positive 10 (12) 8 (18) 21 (9) 10 (9)
Negative 25 (30) 16 (36) 116 (49) 51 (44)
Not performed 48 (58) 21 (47) 102 (43) 55 (47)
Prior platinum-based therapy for R/M disease, n (%)
Cisplatin 35 (42) 18 (40) 133 (56) 65 (56)
Carboplatin 38 (46) 17 (38) 81 (34) 30 (26)
Cisplatin and carboplatin 8 (10) 9 (20) 22 (9) 19 (16)
Other 2 (2) 1 (2) 3 (1) 2 (2)
Prior use of anti-EGFR mAb for R/M disease, n (%)c 49 (59) 30 (67) 140 (59) 68 (59)
Prior surgery, n (%) 62 (75) 32 (71) 182 (76) 90 (78)
Prior curative anticancer therapy,d n (%)
CT only 0 (0) 1 (2) 8 (3) 5 (4)
RT only 28 (34) 14 (31) 49 (21) 23 (20)
CRT 31 (37) 14 (31) 114 (48) 59 (51)
Continued
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Table 1. Continued
Characteristic Patients aged ≥65 years Patients aged <65 years
Afatinib (N = 83) Methotrexate (N = 45) Afatinib (N = 239) Methotrexate (N = 116)
CRT + anti-EGFR mAb 5 (6) 2 (4) 20 (8) 6 (5)
Other 4 (5) 2 (4) 8 (3) 2 (2)
aPercentages may not total 100% due to rounding.
bBased on either local or central test results.
cOne patient (aged <65 years in the afatinib group) received prior panitumumab; all remaining patients received cetuximab.
dInvestigator-reported anticancer therapies with curative intent.
CRT, chemoradiation therapy; CT, chemotherapy; ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; mAb,
monoclonal antibody; PS, performance status; R/M, recurrent and/or metastatic; RT, radiation therapy.
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Figure 1. Kaplan–Meier estimates of (A) PFS and (B) OS by age subgroup. aStratiﬁed log-rank test. CI, conﬁdence interval; HR, hazard ratio; OS, overall
survival; PFS, progression-free survival.
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neutropenia, thrombocytopenia, and leukopenia) with metho-
trexate. There were no notable differences with either treatment
between subgroups in change from baseline in body weight or
ECOG PS (data on ﬁle).
Incidences of treatment-related serious AEs were similar for
afatinib and methotrexate in older (10% and 9%) and younger
(15% and 12%) patients. In both subgroups, afatinib was asso-
ciated with fewer treatment-related dose reductions (older, 36%
versus 43%; younger, 31% versus 41%) and discontinuations
(older, 7% versus 16%; younger, 7% versus 16%). There were no
deaths related to afatinib and one related to methotrexate in
older patients; fewer treatment-related deaths were observed
with afatinib [n = 2 (1%)] compared with methotrexate [n = 4
(3%)] in younger patients.
patient-reported outcomes
In the older and younger subgroups, respectively, ≥90% and
≥95% completed EORTC QoL questionnaires at baseline, and
≥65% and ≥71% across treatment groups completed question-
naires at assessment time points during the ﬁrst 24 weeks of
treatment. There were no notable differences in baseline ques-
tionnaire scores between subgroups (data on ﬁle). A trend
toward improved time to deterioration in global health status
and pain was observed with afatinib versus methotrexate in both
subgroups; a signiﬁcant beneﬁt with afatinib was observed for
time to deterioration in swallowing in older patients (Figure 3).
A signiﬁcant improvement in change in pain over time
(P = 0.015) was observed with afatinib versus methotrexate in
older patients (data on ﬁle).
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Figure 2. Waterfall plot of maximum percentage tumor shrinkage in subgroups of patients aged (A) ≥65 years and (B) <65 years.
 | Clement et al. Volume 27 | No. 8 | August 2016
original articles Annals of Oncology
discussion
The PFS beneﬁt with afatinib over methotrexate was similarly
present in R/M HNSCC patients aged ≥65 or <65 years, and
was associated with a trend toward improvement in some
disease-related symptoms. Although patient numbers in the
older subgroup were smaller than the overall population and
younger subgroup (particularly the methotrexate arm due to the
2:1 randomization scheme), and the study was not powered for
formal statistical comparison of predeﬁned subgroups, there is
no indication that the beneﬁt observed with afatinib would be
adversely affected by advancing age. Median OS, percentage of
patients with tumor shrinkage, ORR, and DCR were also nu-
merically higher with afatinib versus methotrexate in both sub-
groups, with >50% of older patients achieving disease control
with afatinib. Similar to the previous phase III trials in this
setting [8, 11], the 65-year age cutoff was predeﬁned in this
study, and patient numbers in exploratory subgroups aged ≥70
years were too small for meaningful analyses.
In both predeﬁned age subgroups, afatinib was associated
with a trend toward improved patient-reported time to deterior-
ation of global health status, pain and swallowing, reﬂecting the
improvements observed in the overall population [10]. In older
patients, signiﬁcant beneﬁt with afatinib was observed for time
Table 2. Treatment-related AEs in ≥5% of patients (in any group) by age subgroup
Event, n (%) Patients aged ≥65 years Patients aged <65 years
Afatinib (N = 83) Methotrexate (N = 44) Afatinib (N = 237) Methotrexate (N = 116)
Any AE
Any grade Grade 3/4a Any grade Grade 3/4a Any grade Grade 3/4b Any grade Grade 3/4b
80 (96) 31 (37) 39 (89) 15 (34) 223 (94) 94 (40) 98 (85) 37 (32)
Diarrhea 66 (80) 9 (11) 6 (14) 2 (5) 165 (70) 21 (9) 13 (11) 1 (1)
Rash/acnec 64 (77) 6 (7) 4 (9) 0 (0) 174 (73) 25 (11) 9 (8) 0 (0)
Stomatitisd 40 (48) 3 (4) 19 (43) 1 (2) 85 (36) 17 (7) 50 (43) 12 (10)
Fatiguee 19 (23) 7 (8) 15 (34) 2 (5) 60 (25) 11 (5) 36 (31) 3 (3)
Nausea 14 (17) 3 (4) 5 (11) 0 (0) 50 (21) 2 (1) 31 (27) 1 (1)
Paronychiaf 10 (12) 1 (1) 0 (0) 0 (0) 36 (15) 2 (1) 0 (0) 0 (0)
Dry skin 10 (12) 0 (0) 0 (0) 0 (0) 26 (11) 0 (0) 0 (0) 0 (0)
Pruritus 10 (12) 1 (1) 0 (0) 0 (0) 16 (7) 3 (1) 0 (0) 0 (0)
Vomiting 9 (11) 0 (0) 0 (0) 0 (0) 32 (14) 4 (2) 14 (12) 0 (0)
Weight decreased 9 (11) 1 (1) 2 (5) 0 (0) 17 (7) 1 (<1) 3 (3) 0 (0)
Decreased appetite 8 (10) 0 (0) 5 (11) 1 (2) 35 (15) 10 (4) 16 (14) 0 (0)
Epistaxis 6 (7) 0 (0) 0 (0) 0 (0) 11 (5) 0 (0) 1 (1) 0 (0)
Dyspepsia 5 (6) 0 (0) 0 (0) 0 (0) 18 (8) 0 (0) 0 (0) 0 (0)
Anemia 5 (6) 1 (1) 8 (18) 5 (11) 17 (7) 3 (1) 22 (19) 5 (4)
Cheilitis 5 (6) 0 (0) 0 (0) 0 (0) 9 (4) 0 (0) 2 (2) 0 (0)
Muscle spasms 5 (6) 0 (0) 0 (0) 0 (0) 3 (1) 0 (0) 0 (0) 0 (0)
Hypokalemia 4 (5) 2 (2) 1 (2) 0 (0) 9 (4) 5 (2) 3 (3) 1 (1)
Dysgeusia 4 (5) 0 (0) 0 (0) 0 (0) 8 (3) 0 (0) 2 (2) 0 (0)
Blood creatinine increased 4 (5) 0 (0) 0 (0) 0 (0) 4 (2) 0 (0) 1 (1) 0 (0)
Dehydration 4 (5) 2 (2) 0 (0) 0 (0) 3 (1) 3 (1) 0 (0) 0 (0)
Dizziness 4 (5) 0 (0) 0 (0) 0 (0) 3 (1) 0 (0) 0 (0) 0 (0)
Conjunctivitisg 2 (2) 1 (1) 1 (2) 0 (0) 16 (7) 1 (<1) 1 (1) 0 (0)
Palmar-plantar erythrodysethesia 2 (2) 0 (0) 1 (2) 0 (0) 15 (6) 2 (1) 1 (1) 0 (0)
Leukopenia 1 (1) 0 (0) 4 (9) 1 (2) 0 (0) 0 (0) 9 (8) 7 (6)
ALT increased 0 (0) 0 (0) 3 (7) 1 (2) 1 (<1) 0 (0) 12 (10) 2 (2)
Neutropenia 0 (0) 0 (0) 15 (34) 4 (9) 1 (<1) 1 (<1) 16 (14) 7 (6)
Thrombocytopenia 0 (0) 0 (0) 3 (7) 2 (5) 0 (0) 0 (0) 5 (4) 2 (2)
aThere were no grade 5 drug-related AEs observed in ≥5% of patients. In the subgroup of patients aged ≥65 years, there were no patients with grade 5 AEs
in the afatinib group and one patient with grade 5 renal failure and pancytopenia in the methotrexate group not included in the table.
bIn the subgroup of patients aged <65 years, there were two patients with grade 5 AEs in the afatinib group (one aspiration, one septic shock) and four
patients with grade 5 AEs in the methotrexate group (one aspiration, one septic shock, one sepsis, and one general physical health deterioration) not
included in the table.
cGrouped term including acne, dermatitis, dermatitis acneiform, erythema, exfoliative rash, folliculitis, rash, rash erythematous, rash macular, rash
maculopapular, rash pruritic, rash pustular, skin exfoliation, skin fissures, skin lesion, skin reaction, skin toxicity, and skin ulcer.
dGrouped term including aphthous stomatitis, mucosal erosion, mucosal inflammation, mouth ulceration, and stomatitis.
eGrouped term including asthenia, chronic fatigue syndrome, fatigue, and malaise.
fGrouped term including nail bed infection and paronychia.
gGrouped term including conjunctivitis.
AE, adverse event; ALT, alanine aminotransferase.
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to deterioration in swallowing and improvement in pain over
time. Patient-reported outcomes were not analyzed by primary
tumor site, which can impact swallowing ability. In this context,
a larger proportion of older patients had oral cavity primary
site, while more patients in the younger subgroup had orophar-
ynx primary site. In the previous phase III studies of R/M
HNSCC, EGFR-targeted agents have not signiﬁcantly improved
global health status over chemotherapy, although some im-
provements in disease-related symptoms were reported with
ﬁrst-line cetuximab plus chemotherapy; no studies evaluated
QoL or disease-related symptoms speciﬁcally in older patients
[11–13]. While some caution is warranted when interpreting
the patient-reported outcomes data for older patients in this
study due to smaller patient numbers, ﬁndings suggest that afa-
tinib may provide some QoL beneﬁt over methotrexate in these
patients.
Treatment compliance is an important factor for clinical out-
comes in older patients, as they are vulnerable to nonadherence
due to health-related and socioeconomic factors (e.g. logistical
complications and hospital transportation) [14]. In this study,
treatment exposure with afatinib was similar in older and
younger patients, and compliance rates were high with afatinib
versus methotrexate in both subgroups. Further, no unexpected
safety ﬁndings with afatinib were observed in older patients,
with an AE proﬁle that was predictable and manageable, and
generally similar to younger patients. Of note, there were some
differences in baseline prior therapies that may impact tolerabil-
ity, including less intensive therapy in the curative setting in the
older subgroup (i.e. more patients received radiotherapy alone
and fewer received chemoradiation compared with younger
patients), although no analysis of timing of curative therapy was
performed, and a greater proportion of older patients receiving
carboplatin over cisplatin in the ﬁrst-line R/M setting compared
with younger patients. Consistent with the overall study, fewer
treatment-related dose reductions and discontinuations were
observed with afatinib versus methotrexate in both subgroups,
with no afatinib-related deaths occurring in older patients.
These ﬁndings suggest that advancing age did not adversely
affect the favorable safety proﬁle of afatinib in this study.
There are some study limitations that should be considered
when interpreting these ﬁndings, particularly for patients aged
≥65 years. There is no standard deﬁnition for ‘older’ or ‘elderly’;
however, much of the literature deﬁnes patients aged ≥65 years
as ‘older’, with subcategories of ‘young old’ (65–74 years), ‘old’
(75–85 years), and ‘oldest old’ (>85 years) [3, 4]. In this study,
25% of patients included in the ≥65 years subgroup were aged
≥75 years, categorizing the majority as ‘young old’. This is not
unexpected, as patients aged ≥75 years are often underrepre-
sented in clinical trials due to exclusion criteria preventing en-
rollment of patients with high comorbidity burden and poor
functional status, which are routinely observed with advancing
age, particularly in HNSCC patients. In this trial, patients with
ECOG PS ≥2 (due to the lack of prior experience with afatinib
in R/M HNSCC patients with ECOG PS >1) and/or signiﬁcant
comorbidities (e.g. cardiovascular abnormalities, gastrointestinal
disorders) were excluded, resulting in similar functional status
and baseline medical conditions between subgroups. Further,
there was no formal geriatric assessment to deﬁne frailty of the
patients enrolled; thus, patients in the ≥65 years subgroup are
considered to be relatively ﬁt, warranting a certain degree of
caution when considering treatment of a frailer population.
Despite these limitations, patients aged ≥65 years represented a
substantial proportion (27%) of the total study population, with
a ∼15-year difference in median age observed between sub-
groups. This allowed for meaningful comparison of clinical
outcomes based on the age cutoff of ≥65 years, ultimately dem-
onstrating similar treatment effects of afatinib and methotrexate
in these subgroups. These ﬁndings support the concept that
chronological age alone should not be a determining factor in
treatment choice, and other factors including functional status,
comorbidities, and frailty should be considered [4]. Ongoing
trials in HNSCC patients aged ≥70 years have incorporated geri-
atric evaluation to deﬁne patient frailty and deliver more perso-
nalized treatment (ELAN trials) [15].
In summary, effective anticancer treatment and management
of tolerability in older R/M HNSCC patients is a signiﬁcant
challenge. In the LHN1 study, similar outcomes with regard to
efﬁcacy and patient-reported outcomes of QoL and disease-
related symptoms were observed with afatinib versus methotrex-
ate in the second-line R/M HNSCC patients aged ≥65 and <65
years. Further, afatinib demonstrated a predictable and manage-
able safety proﬁle in both subgroups.
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